Central hypovolemia, frequently resulting from blood loss or shifts in vascular volume, presents significant challenges in clinical and emergency settings. The body’s response involves a cascade of ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...

KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and ...

Septic shock affects more than 230,000 U.S. patients each year, but JAMA has published new advances in diagnosing and treating this clinical emergency in hopes of reducing that number. Here are three ...